AnaptysBio
ANAB
147 hedge funds and large institutions have $816M invested in AnaptysBio in 2025 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 45 increasing their positions, 55 reducing their positions, and 31 closing their positions.
83% more call options, than puts
Call options by funds: $5.28M | Put options by funds: $2.89M
10% more capital invested
Capital invested by funds: $743M → $816M (+$73.4M)
0.47% more ownership
Funds ownership: 132.3% → 132.78% (+0.47%)
4% less funds holding
Funds holding: 153 → 147 (-6)
13% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 31
18% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 55
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$28.6M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$16.4M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$7.37M |
| 4 |
6CM
683 Capital Management
New York
|
+$6.37M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$5.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.4M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$24.2M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$22.9M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$13.1M |
| 5 |
BlackRock
New York
|
-$8.16M |
ANAB Hedge Fund Activity: Q2 2025 in Review
147 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q2 2025, worth a combined $816M — up 9.9% from $743M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of ANAB and 27 opened new positions — a net loss of 4 holders — while 55 trimmed existing stakes and 45 added.
The largest buyer was Morgan Stanley, adding an estimated $28.6M. The largest seller was Fidelity Investments, cutting an estimated $38.4M.
- 147 institutional investors held AnaptysBio (ANAB) as of Q2 2025, down from 153 in Q1 2025.
- Funds reported $816M of AnaptysBio stock for Q2 2025, up 9.9% quarter-over-quarter.
- 27 funds opened new AnaptysBio positions in Q2 2025 and 31 closed out, a net change of -4 holders.
- The largest AnaptysBio buyer in Q2 2025 was Morgan Stanley, an estimated $28.6M added.
- The largest AnaptysBio seller in Q2 2025 was Fidelity Investments, an estimated $38.4M sold.
Based on aggregated 13F filings for Q2 2025.